21. The prognostic value of survival time by the abcr score in patients with hepatocellular carcinoma (HCC) treated with trans - arterial chemo - embolization (TACE) at Hanoi Medical University Hospital
Main Article Content
Abstract
About 60% of Hepatocellular carcinoma (HCC) patients are detected in the intermediate stage according to Barcelona, and the main treatment in this stage is transarterial chemoembolization (TACE). However, not all patients achieve the same results from TACE treatment. Therefore, the ABCR score was born to assist with predicting re-treatment of HCC with TACE method. We conducted this study to evaluate the value of the ABCR scoring system in predicting the additional survival time in patients with intermediate stage HCC treated with TACE method. 85 patients recruited for this study were treated at Hanoi Medical University hospital from June 2021 to January 2024. The average age of our study group was 59.7 ± 10.9 years old. Male accounted for 85.9%. 72.9% of patients have hepatitis B. The average survival time after TACE was 33.5 months. The value for predicting mortality prognosis of the ABCR score has an area under the curve of 0.67. The low-risk ABCR classification group had a median survival time of 36,6 months with a 95% CI of 33.6 - 39.6, higher than the intermediate-risk ABCR classification group and high-risk ACBR classification group (33.4 months and 14.7 months) with p = 0.07.
Article Details
Keywords
Hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE), ABCR score, Hanoi Medical University Hospital
References
2. Masatoshi Kudo TA KU, Toshiharu Sakurai, Masayuki Kitano, Naoshi Nishida. . Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi’s Subclassification (Kinki Criteria). Dig Dis. 2015; 33(6): 751-758. doi:doi:10.1159/000439290.
3. Nguyễn Trường Sơn. Chẩn đoán và điều trị Ung thư biểu mô tế bào gan. Bộ y tế. 2020;
4. Amit G JMea. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 76(6): 1922-1965. doi:10.1097/HEP.0000000000000466.
5. Xavier Adhoute GP, Sebastien Naude. Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process. Journal of Hepatology. 2015; 62(4): 855-862.
6. Đậu Quang Liêu. Nghiên cứu giá trị thang điểm mHAP - II trong tiên lượng thời gian sống thêm ở bệnh nhân ung thư biểu mô tế bào được điều trị nút mạch. trường đại học Y Hà Nội; 2022.
7. Nguyễn Đình Tùng. Cancer incidence in the population of Thua Thien Hue province, Viet Nam 2001-2009. Journal of Science, Hue University. 2012; 61
8. Kefeng Jia WY, Zhongsong Gao. Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients. Eur J Gastroenterol Hepatol. 2023; 35(4): 461–470.
9. Doãn Thái kỳ. Nghiên cứu kết quả điều trị ung thư biểu mô tế bào gan bằng phương pháp tắc mạch hóa dầu sử dụng hạt vi cầu Dc Beads. . Viện Nghiên cứu khoa học y dược lâm sàng 108. 2015;
10. Yehyun Park et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36:100-107.
11. Gauri Mishra et al. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer. 2020; 29(20): 483.
12. Shi Z WD, Kang T, Yi R, Cui L, Jiang H. Radiol Oncol. 2023; 57: 70–79. Comparison of CalliSpheres(®) microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial. Radiol Oncol. 2023; 57: 79-70.
13. Adhoute X PG, Naude S, Raoul JL, Perrier H, Bayle O, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015; 64(4): 855-862.